Moreover, androgen deprivation therapy (ADT), provided to intermediate17, 18, 19, 20 and high-risk21, 22, 23, 24 patients with prostate cancer before, during, or after RT further suppresses PSA secretion. This evidence concerns the gene KLK3 and prostate carcinoma.